RDUS Radius Health, Inc.

-1.27  -4%
Previous Close 36.20
Open 36.03
Price To book 5.97
Market Cap 1.52B
Shares 43,377,000
Volume 1,348,866
Short Ratio 7.78
Av. Daily Volume 1,093,660

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due mid-2017.
Elacestrant (RAD1901)
Vasomotor symptoms
PDUFA date originally scheduled for March 30 2017 delayed by three months to June 30, 2017. Approval announced April 28, 2017.
TYMLOS (Abaloparatide)

Latest News

  1. Radius Health Osteoporosis Drug Positive in Phase III Study
  2. Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS™ in Postmenopausal Women with Osteoporosis
  3. Today's Research Reports on Stocks to Watch: Radius Health and Biocept Inc.
  4. Radius Health Spikes 20% After Amgen Osteoporosis Drug Derailed
  5. Amgen Can Shrug Off Its Bone-Drug Risks
  6. Here's Why Radius Health Gained as Much as 20.2% Today
  7. [$$] Safety risk for Amgen and UCB's bone drug lifts rival Radius
  8. Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In
  9. Biotech Movers: Radius Health, Amgen, Paratek
  10. Radius Health Announces New Employment Inducement Grant
  11. Radius Health Appoints Pharmaceutical Executive Jose Carmona as Chief Financial Officer
  12. Huge Hedge Fund, Biotech and Technology Trades Highlight Insider Buying: Apollo Global, Biogen, Twitter, DDR and More
  13. Radius Health, Inc. (Nasdaq: RDUS) to Ring The Nasdaq Stock Market Opening Bell
  14. Insiders Are Loading Up on Twitter, Biogen & More
  15. Edited Transcript of RDUS earnings conference call or presentation 1-May-17 11:30am GMT
  16. Investor Network: Radius Health Inc. to Host Earnings Call
  17. Why Intra-Cellular Therapies, Wesco Aircraft Holdings, and Radius Health Slumped Today
  18. Radius Health (RDUS) Q1 Earnings: What's in Store?
  19. Why Radius Health Inc. Is Dropping Today